[Treatment of extrahepatic manifestations associated with hepatitis C virus infection].
Cacoub
Patrice
P
Service de Médecine Interne, Hôpital La Pitié-Salpêtrière, Paris.
D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects; D001323:Autoantibodies / Q000276:immunology; D003449:Cryoglobulinemia / Q000209:etiology / Q000628:therapy; D004359:Drug Therapy, Combination; D005221:Fatigue / Q000209:etiology; D005260:Female; D015432:Glomerulonephritis, Membranoproliferative / Q000209:etiology; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects; D008232:Lymphoproliferative Disorders / Q000209:etiology; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D017119:Porphyria Cutanea Tarda / Q000209:etiology / Q000628:therapy; D011537:Pruritus / Q000209:etiology; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects; D012859:Sjogren's Syndrome / Q000209:etiology / Q000628:therapy; D011795:Surveys and Questionnaires; D013921:Thrombocytopenia / Q000209:etiology / Q000628:therapy; D013997:Time Factors; D014652:Vascular Diseases / Q000209:etiology / Q000628:therapy
D000998:Antiviral Agents; D001323:Autoantibodies; D012254:Ribavirin; D007372:Interferons